Autopsy report · NCT04575519
Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
Cause of deathStaffing, sites or logistics, also slow enrollment
“The impact of the COVID-19 pandemic on TB diagnosis affected greatly the recruitment rate and posed challenges to the trial's timeline, consuming the funding needed to continue the enrolment.”
Life of this trial
- Registered 7 months before it started.
- Ran for about 3 years before it stopped.
- 426 participants enrolled.
- Results were posted on the registry 2 years 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Fundació Institut Germans Trias i Pujol
- Sponsor type
- University, hospital or other
- Conditions
- Tuberculosis, Pulmonary; Tuberculosis, MDR; Tuberculosis Infection
- Interventions
- Control group; ASA group; IBU group; SoC TB
- Participants
- 426
- Sites
- 3
- Countries
- Georgia, South Africa
Trials that died the same way
- Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation
“COVID-19 pandemic adversely affected recruitment.” - Laser Treatment for Vulvar Lichen Sclerosus
“Recruitment was significantly impacted by the COVID-19 pandemic.” - A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients
“Difficulty with patient recruitment due to COVID-19” - Sleep, Insulin Sensitivity, and Weight in Adolescents Post-bariatric Surgery
“COVID-19 pandemic impacted recruitment” - Pathology and Imaging in Kidney Allografts
“recruitment difficulties due to impact of COVID-19 pandemic”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.